Introduction Learning Objectives Introduction

Introduction

Watch a series of internationally renowned clinical specialists from Europe and Japan discuss key clinical data of interest from the San Antonio Breast Cancer Symposium (SABCS) 2018 Congress, 3–8 December 2018.

The potential implications of these data for optimizing clinical outcomes for patients with advanced breast cancer are explored from both global and regional perspectives.

The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.

Learning Objectives

After watching these touchCONGRESS Expert Opinions from SABCS 2018, you should be able to:

Discuss key data of interest from SABCS 2018 in advanced breast cancer and what they may mean for local clinical practice.
Apply clinical trial evidence to inform sequencing of therapies and duration of treatment in patients with advanced breast cancer.
Review the identification of prognostic and differentiation factors to drive the optimal use of chemotherapy, endocrine therapy and combination therapy with targeted agents such as CDK4/6 inhibitors.

Professor Wolfgang
Janni

Professor Janni, Director of the Department of Obstetrics and Gynecology at the University of Ulm, Germany, provides his expert insight into key data presented at SABCS 2018, and what they may mean for optimizing clinical outcomes for patients with advanced breast cancer.

Clinical Spotlight

To what extent have new data presented at SABCS 2018 helped answer how patients with HR+/HER2- disease can receive therapy that also supports their quality of life?
How do CDK4/6 inhibitor dose reductions influence the benefits of treatment for HR+/HER2- advanced breast cancer, and is there any subsequent impact on routine clinical practice?
Does patient age or health status have any influence on the selection or treatment sequence with CDK4/6 inhibitors? For example, should elderly or frail patients be managed differently?
There are interesting data in a small group of highly pre-treated patients with leptomeningeal metastases. What implications does this have for CDK4/6 inhibitors, if any?
The SONIA study aims to test the optimal sequencing of CDK4/6 inhibitors for patients with HR+/HER2- advanced breast cancer. What is current best practice and is there a position for endocrine monotherapy?
Were there any CDK4/6 inhibitor data that stood out for you at the 2018 SABCS meeting, and what are their implications (if any) for the current management of patients from a local perspective?

About Professor Wolfgang
Janni

Wolfgang Janni, is a full Professor and Director of the Department of Obstetrics and Gynecology at the University of Ulm, Germany. He is a board-certified gynaecologist, with subspecialties in gynaecological oncology, breast cancer, and perinatal medicine. In 2016 he was appointed as chair of the German Guideline Council for Breast Cancer (AGO), and as an elected member of the National Academy of Science Leopoldina in 2018.

Prof Janni’s research has received numerous international awards, including awards from the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), and San Antonio Breast Cancer Symposium (SABCS). He is an editorial board member of several renowned peer-reviewed journals.

Disclosures: Honoraria and research grants from Novartis, Pfizer, Amgen, Chugai, Roche, Genomic-Health, AstraZeneca, Lilly

touchCONGRESS Expert Opinions
SABCS 2018

Touch Oncology

touchCONGRESS Expert Opinions

Continuing the conversation with CDK4/6 inhibitors in advanced breast cancer from SABCS 2018

Introduction

Learning Objectives

Please feedback on this touchCONGRESS Expert Opinions on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).

touchCONGRESS Expert OpinionsSABCS 2018

LOGIN or REGISTER to access this content

Introduction

Learning Objectives

Please feedback on this touchCONGRESS Expert Opinions on the following:(scale 1-5, 1 strongly disagree; 5 strongly agree).

touchCONGRESS Expert Opinions
SABCS 2018

Please feedback on this touchCONGRESS Expert Opinions on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).